193 related articles for article (PubMed ID: 29488681)
1. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
2. The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2).
Bruserud Ø
Toxins (Basel); 2013 Apr; 5(4):665-74. PubMed ID: 23594438
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
[TBL] [Abstract][Full Text] [Related]
5. Thrombomodulation via CLEC-2 targeting.
O'Callaghan CA
Curr Opin Pharmacol; 2009 Apr; 9(2):90-5. PubMed ID: 19091630
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
7. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.
Nagae M; Morita-Matsumoto K; Kato M; Kaneko MK; Kato Y; Yamaguchi Y
Structure; 2014 Dec; 22(12):1711-1721. PubMed ID: 25458834
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC-2.
Watson AA; O'Callaghan CA
Toxins (Basel); 2011 Aug; 3(8):991-1003. PubMed ID: 22069753
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of platelet aggregation by affinity captured rhodocytin from the Malayan pit viper Calloselasma rhodostoma.
Feickert MK; Sanz-Soler R; Niland S; König S; Eble JA; Obermann WMJ
Toxicon; 2023 Mar; 225():107058. PubMed ID: 36806336
[TBL] [Abstract][Full Text] [Related]
10. The novel platelet activation receptor CLEC-2.
Suzuki-Inoue K; Inoue O; Ozaki Y
Platelets; 2011; 22(5):380-4. PubMed ID: 21714702
[TBL] [Abstract][Full Text] [Related]
11. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
[TBL] [Abstract][Full Text] [Related]
13. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
Suzuki-Inoue K
J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
[TBL] [Abstract][Full Text] [Related]
14. A change of rhodocytin's suprastructure turns the agonist into an antagonist of tumor cell induced platelet aggregation.
Obermann WMJ; König S; Feickert MK; Sanz-Soler R; Eble JA
FASEB J; 2024 Jan; 38(2):e23402. PubMed ID: 38193585
[TBL] [Abstract][Full Text] [Related]
15. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
Sheng M; Sun R; Fu J; Lu G
BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
[TBL] [Abstract][Full Text] [Related]
16. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
[TBL] [Abstract][Full Text] [Related]
17. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
[TBL] [Abstract][Full Text] [Related]
18. CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP.
Borgognone A; Navarro-Núñez L; Correia JN; Pollitt AY; Thomas SG; Eble JA; Pulcinelli FM; Madhani M; Watson SP
J Thromb Haemost; 2014 Apr; 12(4):550-9. PubMed ID: 24460629
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2.
Watson AA; Eble JA; O'Callaghan CA
Protein Sci; 2008 Sep; 17(9):1611-6. PubMed ID: 18583525
[TBL] [Abstract][Full Text] [Related]
20. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
